ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms

Annals of Surgical Oncology

Volumn 20, Issue 1, 2013, Pages 200-208

  Lee, Hee Jin ^a   Seol, Hyang Sook ^b   Kim, Joo Young ^c   Chun, Sung Min ^b   Suh, Young Ah ^b   Park, Young Soo ^b   Kim, Sang We ^b   Choi, Chang Min ^b   Park, Seung Il ^b   Kim, Dong Kwan ^b   Kim, Yong Hee ^b   Jang, Se Jin ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN TYROSINE KINASE; ROS1 RECEPTOR TYROSINE KINASE; STAT3 PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; EPIGENETICS; FEMALE; GENDER; GENE OVEREXPRESSION; GROUPS BY AGE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; OVERALL SURVIVAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SMOKING; SURVIVAL TIME; UPREGULATION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-VAV; STAT3 TRANSCRIPTION FACTOR;

EID: 84871784888     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2553-6     Document Type: Article

References (33)

1. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-203.
2. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795:37-52.
3. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci USA. 1987;84:9270-4.
4. Mapstone T, McMichael M, Goldthwait D. Expression of platelet-derived growth factors, transforming growth factors, and the ros gene in a variety of primary human brain tumors. Neurosurgery. 1991;28:216-22.
5. Watkins D, Dion F, Poisson M, et al. Analysis of oncogene expression in primary human gliomas: evidence for increased expression of the ros oncogene. Cancer Genet Cytogenet. 1994;72:130-6.
6. Zhao JF, Sharma S. Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet. 1995;83:148-54.
7. Jun HJ, Woolfenden S, Coven S, et al. Epigenetic regulation of c-ROS receptor tyrosine kinase expression in malignant gliomas. Cancer Res. 2009;69:2180-4.
8. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790-5.
9. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784-9.
10. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-7.
11. Alian G, Anthony P. Translocation and mutant ROS kinase in human non-small cell lung carcinoma. US Patent 0,298,404, 25 Nov 2010.
12. Ting-Lei G, Alian G. Translocation and mutant ROS kinase in human non-small cell lung carcinoma. US Patent 0,221,737, 2 Sept 2010.
13. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-70.
14. Ellis L, Morgan DO, Jong SM, et al. Heterologous transmembrane signaling by a human insulin receptor-v-ros hybrid in Chinese hamster ovary cells. Proc Natl Acad Sci USA. 1987;84:5101-5.
15. Xiong Q, Chan JL, Zong CS, Wang LH. Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth. Mol Cell Biol. 1996;16:1509-18.
16. Riethmacher D, Langholz O, Godecke S, et al. Biochemical and functional characterization of the murine ros protooncogene. Oncogene. 1994;9:3617-26.
17. Nguyen KT, Zong CS, Uttamsingh S, et al. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in Ros-induced cell transformation. J Biol Chem. 2002;277:11107-15.
18. Zong CS, Zeng L, Jiang Y, et al. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem. 1998;273:28065-72.
19. Schmitz AA, Govek EE, Bottner B, Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res. 2000;261:1-12.
20. Zeng L, Sachdev P, Yan L, et al. Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol. 2000;20:9212-24.
21. El-Deeb IM, Yoo KH, Lee SH. ROS receptor tyrosine kinase: a new potential target for anticancer drugs. Med Res Rev 2011;31:794-818.
22. El-Deeb IM, Park BS, Jung SJ, et al. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009;19:5622-6.
23. Park BS, El-Deeb IM, Yoo KH, et al. Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Bioorg Med Chem Lett. 2009;19:4720-3.
24. Legare C, Sullivan R. Expression and localization of c-ros oncogene along the human excurrent duct. Mol Hum Reprod. 2004;10:697-703.
25. Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer. 2003;37:58-71.
26. Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6:e15640.
27. De Smet C, De Backer O, Faraoni I, et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci USA. 1996;93:7149-53.
28. Honda T, Tamura G, Waki T, et al. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer. 2004;90:838-43.
29. Yanagawa N, Tamura G, Oizumi H, et al. MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer. Anticancer Res. 2011;31:171-5.
30. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res. 2006;4:339-49.
31. Stoecklein NH, Klein CA. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer. 2010;126:589-98.
32. Dupont Jensen J, Laenkholm AV, Knoop A, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17:667-77.
33. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061-8.